Please login to the form below

Synagis

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Synagis was produced by AstraZeneca and AbbVie.

Sobi shows strong growth despite haemophilia competition

November also saw Sobi acquire rights to Synagis, the only approved respiratory syncytial virus (RSV) prophylaxis for high-risk infants from AstraZeneca. ... We completed the acquisition of Synagis in late January and are in the process of integrating

US, EU regulators back rapid reviews of AZ’s RSV med

MEDI8897 is a longer-acting follow-up to AZ’s Synagis (palivizumab), which is currently the only drug approved for preventing RSV in high-risk patients. ... Synagis has been a nice earner for AZ, making almost $700m in revenues in 2017, but has started

FDA clears Sobi’s Gamifant for ‘hyper-inflammation’ disease

Earlier this month, Sobi agreed to acquire the US rights to AstraZeneca’s respiratory syncytial virus (RSV) prevention drug Synagis (palivizumab) in a deal worth $1.5bn. ... Sobi's Guido Oelkers. “Gamifant will add significant strength to Sobi’s

AZ cuts $1.5bn-plus deal to pass US drug rights to Sobi

s focus on Synagis will enable infants in the US to continue benefiting from this important treatment.”. ... The addition of Synagis will become an important strategic catalyst for Sobi’s future development and will form a powerful platform for

Ablynx spurns Novo Nordisk and cuts €3.9bn deal with Sanofi

AZ sells a prophylactic RSV antibody - Synagis (palivizumab) - which brought in $677m in sales in 2016 despite being reserved for use in high-risk infants.

1 2 3 4 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology